Augmedix announced the establishment of an AI Advisory Council. The healthcare industry’s adoption of AI is growing very rapidly and Augmedix is committed to harnessing the power of AI thoughtfully and responsibly to provide its customers with solutions they can trust. The Advisory Council will provide advice and guidance to the Augmedix senior leadership team on matters related to the integration of AI into the Company’s product development roadmap. The AI Advisory Council will be led by Joe Marks, Ph.D., who has served as a director of the Company since 2020. Previously he was the Executive Director of Carnegie Mellon University’s Center for Machine Learning and Health. Members of the council will include distinguished industry thought leaders from computer science, bioinformatics, digital healthcare, as well as Augmedix customers. These individuals will bring diverse expertise and perspectives from academic institutions, corporate entities from various sectors, healthcare industry associations, as well as civil society organizations associated with AI. The council will hold a variety of responsibilities, including discussing regulatory frameworks, evaluating risks and opportunities for ambient medical documentation product development, reviewing AI applications and algorithms, monitoring and addressing ethical concerns, providing strategic advice and engaging with key stakeholders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUGX:
- Augmedix Establishes AI Advisory Council to Guide the Company’s Continued Development of High Standard, Responsible Product Development
- Augmedix Announces Participation in Upcoming Investor Conferences
- Augmedix Delivers Continued Sales Momentum; Reports First Quarter 2023 Financial Results
- Augmedix price target raised to $8 from $5 at Maxim
- Augmedix price target raised to $6 from $5 at Benchmark
